Quercetin, a Promising Clinical Candidate for The Prevention of Contrast-Induced Nephropathy

• Published in: International journal of molecular sciences 2019-10, Vol.20 (19), p.4961
• Main Authors: Vicente-Vicente, Laura, González-Calle, David, Casanova, Alfredo Ginés, Hernández-Sánchez, María Teresa, Prieto, Marta, Rama-Merchán, Juan Carlos, Martín-Moreiras, Javier, Martín-Herrero, Francisco, Sánchez, Pedro Luis, López-Hernández, Francisco J, Cruz-González, Ignacio, Morales, Ana Isabel
• Format: Article
• Language: English
• Subjects: Aged; Antioxidants; Biomarkers; Catheterization; Contrast media; Contrast Media - administration & dosage; Contrast Media - adverse effects; Contrast Media - classification; Creatinine; Creatinine - metabolism; Damage prevention; Drug dosages; Female; Flavonoids; Glomerular filtration rate; Glomerular Filtration Rate - drug effects; Humans; Ischemia; Kidney diseases; Kidney Diseases - diagnosis; Kidney Diseases - etiology; Kidney Diseases - metabolism; Kidney Diseases - prevention & control; Male; Nephropathy; Oxidative stress; Pathogenesis; Patients; Protective Agents - pharmacology; Protective Agents - therapeutic use; Quercetin; Quercetin - pharmacology; Quercetin - therapeutic use; Renal failure; Risk factors
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms20194961

Iodinated contrast media (CM) are the leading cause of acute renal failure of toxic origin. Between 21% and 50% of patients that receive them develop contrast-induced nephropathy (CIN). All prophylactic measures used so far have failed to provide effective prevention. Since oxidative stress is involved in the damage, a possible preventive strategy could be the administration of antioxidant substances, such as quercetin. This compound has shown renoprotective effects in experimental studies. The aim of this study was to evaluate whether quercetin may be helpful in preventing CIN in patients undergoing coronary catheterization. A clinical phase II study was conducted. Patients were distributed in two groups, namely, CM (patients who only received contrast media) and CM+Q (patients who were pretreated with quercetin orally for 3-5 days). Results showed less incidence of CIN in the CM+Q group, possibly due to glomerular protection, evidenced by a lower increase in serum creatinine and albuminuria; and a lower decrease in the glomerular filtration rate (GFR). Furthermore, in this group, the relative risk of developing CIN observed in patients that received a high dose of contrast media was inferior. In conclusion, this is the first study that demonstrates that quercetin is a promising safe candidate in preventing CIN.